Search research articles
Contact Us
Filters
Showing results (71-80 of 162) with videos related to
Page
of 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2006
First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy
Serena Merante, Merante Serena, Guido Chichino, et al.
American Journal of Hematology
|
February 5, 2024
Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia
Adela Benesova, Sara De Santis, Vaclava Polivkova, et al.
Oncotarget
|
April 14, 2017
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy
Simona Luatti, Carmen Baldazzi, Giulia Marzocchi, et al.
Journal of Cellular Biochemistry
|
April 13, 2017
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage
Manuela Mancini, Fausto Castagnetti, Simona Soverini, et al.
Leukemia Research
|
March 19, 2011
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia
Ilaria Iacobucci, Marco Sazzini, Paolo Garagnani, et al.
British Journal of Haematology
|
June 24, 2009
Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation
Leonardo Potenza, Francesco Volzone, Giovanni Riva, et al.
BMC Cancer
|
April 4, 2013
Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
Andrew M Stein, Giovanni Martinelli, Timothy P Hughes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 31, 2012
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib
Susan Branford, Dong-Wook Kim, Simona Soverini, et al.
Haematologica
|
May 3, 2014
Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms
Tariq I Mughal, Alessandro M Vannucchi, Simona Soverini, et al.
Blood
|
May 13, 2011
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
Simona Soverini, Andreas Hochhaus, Franck E Nicolini, et al.
Page
of 17
Search research articles
Search
Showing results (71-80 of 162) with videos related to
Sort By:
Page
of 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2006
First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy
Serena Merante, Merante Serena, Guido Chichino, et al.
American Journal of Hematology
|
February 5, 2024
Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia
Adela Benesova, Sara De Santis, Vaclava Polivkova, et al.
Oncotarget
|
April 14, 2017
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy
Simona Luatti, Carmen Baldazzi, Giulia Marzocchi, et al.
Journal of Cellular Biochemistry
|
April 13, 2017
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage
Manuela Mancini, Fausto Castagnetti, Simona Soverini, et al.
Leukemia Research
|
March 19, 2011
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia
Ilaria Iacobucci, Marco Sazzini, Paolo Garagnani, et al.
British Journal of Haematology
|
June 24, 2009
Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation
Leonardo Potenza, Francesco Volzone, Giovanni Riva, et al.
BMC Cancer
|
April 4, 2013
Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
Andrew M Stein, Giovanni Martinelli, Timothy P Hughes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 31, 2012
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib
Susan Branford, Dong-Wook Kim, Simona Soverini, et al.
Haematologica
|
May 3, 2014
Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms
Tariq I Mughal, Alessandro M Vannucchi, Simona Soverini, et al.
Blood
|
May 13, 2011
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
Simona Soverini, Andreas Hochhaus, Franck E Nicolini, et al.
Page
of 17